BlackRock Enhanced Equity Dividend Trust (NYSE: BDJ) director reports no reportable stake

Corbus Pharmaceuticals updated its corporate presentation, reporting progress in CRB-701 for OPSCC and positive Phase 1b results for CRB-913 in obesity. The company has $118M in cash and expects interim ORR readout for CRB-701 in Q1 2027. CRB-913 showed ~5% placebo-adjusted weight loss at 12 weeks, with Phase 2 trials planned for 1H 2027.

Stifel reiterated a Buy rating and $60 price target on GlobalFoundries (GFS) after its Japan fab deal. The company will operate two 300mm facilities funded by up to $21B from Japan, with the first facility expected in 2029. GFS projects long-term EPS accretion of $0.50-$0.75 from the first facility. Analysts show strong conviction, with consensus targets pointing to 53% upside potential.

Stifel raised its price target for Mirum Pharmaceuticals (MIRM) to $156 from $136, citing recent clinical and regulatory achievements. The stock trades at $82.64, with strong revenue growth of 44% over the last year, reaching $618 million. Analysts highlight multiple expansion opportunities and a potential peak portfolio value of over $4 billion. The stock has declined 17% over the past six months, but analysts maintain a positive outlook.

Toyota Australia agreed to a AU$750 million settlement for class actions over diesel particulate filter (DPF) issues in HiLux, Prado, and Fortuner models, pending court approval. The settlement covers 264,170 vehicles sold between 2015 and 2020, with defects reducing vehicle value. Toyota Motor Corporation stated the payout is immaterial to its finances.

RTX Corp.'s Raytheon unit was chosen to upgrade U.S. Space Force radars, enhancing missile launch detection and space object monitoring. The project aims to boost performance and reliability. According to the company, this selection underscores the military's focus on advancing its radar capabilities.

Krystal Biotech (NASDAQ:KRYS) reported that its investigational immunotherapy KB113 showed regression in 83% of assessed basal cell carcinoma lesions in a pilot study of three Gorlin syndrome patients. The company has begun FDA discussions for further development. Biopsies confirmed complete responses in three lesions. The study is small and preliminary, with larger trials needed to confirm efficacy and safety.